What the FDA labels say about taking them together
Lanreotide and nateglinide
Nateglinide's FDA label of February 24, 2025 names lanreotide in its drug interactions section; the lanreotide labels PlainMeds reads (2) do not name nateglinide. The nateglinide label: “Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin …”
Check it at the source: the lanreotide FDA label on DailyMed (effective October 11, 2024, Ipsen Biopharmaceuticals, Inc.); the nateglinide FDA label on DailyMed (effective February 24, 2025, Strides Pharma Science Limited).
What does the lanreotide label say about nateglinide?
Lanreotide's label (effective October 11, 2024) and its 1 other brand-application label do not name nateglinide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (SOMATULINE DEPOT), Ipsen Biopharmaceuticals, Inc., effective October 11, 2024 (SPL set 6e4a41fd-a753-4362-87ee-8cc56ed3660d), via openFDA; the full label on DailyMed
What does the nateglinide label say about lanreotide?
Nateglinide label, drug interactionsDrugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). Intervention: Dose increases and increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs.
Source: FDA drug label (Nateglinide), Strides Pharma Science Limited, effective February 24, 2025 (SPL set 0ccf9b07-3c21-482d-abeb-a06ceb482c7b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lanreotide | Nateglinide | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.179 per tablet 60 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once